Effect of Hypoglycemic Drugs on Patients with Heart Failure with or without T2DM: A Bayesian Network Meta-analysis

Figures

• 

  Fig. 1.. Flow diagram of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) criteria. RCTs, randomized controlled trials.

• 

  Fig. 2.. Traffic light plot for the risk-of-bias assessment of included trials.

• 

  Fig. 3.. The network graph for all outcomes. (A) Re-admission due to HF; (B) all-cause death; (C) cardiovascular death; (D) NTpro-BNP; (E) LVEF. GLP1, glucagon-like peptide1; HF, heart failure; NTpro-BNP, N-terminal pro-brain natriuretic peptide; LVEF, left ventricular ejection fraction.

• 

  Fig. 4.. Comparison of re-admission due to heart failure (HF). The values in each cell represent the relative treatment effect (95% credible intervals (CrI)) of the treatment on the right compared with the treatment on the top.

• 

  Fig. 5.. Rankogram for all outcomes. Each line segment represents a treatment. The area enclosed by the line segment and the coordinate axis represents the cumulative probability of treatment. (A) Readmission due to HF; (B) all-cause death; (C) cardiovascular death; (D) NTpro-BNP; (E) LVEF.

• 

  Fig. 6.. Comparison of all-cause death. The values in each cell of the league table heatmap represent the relative treatment effect (95% CrI) of the treatment on the right compared with the treatment on the top.

• 

  Fig. 7.. Comparison of cardiovascular death. The values in each cell of the league table heatmap represent the relative treatment effect (95% CrI) of the treatment on the right compared with the treatment on the top.

• 

  Fig. 8.. Comparison of changes in serum NTpro-BNP levels. The values in each cell of the league table heatmap represent the relative treatment effect (95% CrI) of the treatment on the right compared with the treatment on the top.

• 

  Fig. 9.. Comparison of changes in left ventricular ejection fraction. The values in each cell of the league table heatmap represent the relative treatment effect (95% CrI) of the treatment on the right compared with the treatment on the top.

• 

  Fig. 10.. Rankogram for all outcomes of the subgroup with HErEF. Each line segment represents a treatment. The area enclosed by the line segment and the coordinate axis represents the cumulative probability of treatment. (A) Readmission due to HF; (B) all-cause death; (C) cardiovascular death; (D) LVEF. HErEF, HF with reduced ejection fraction.

• 

  Fig. 11.. Rankogram for all subgroup outcomes with type 2 diabetes mellitus (T2DM). Each line segment represents a treatment. The area enclosed by the line segment and the coordinate axis represents the cumulative probability of treatment. (A) Readmission due to HF; (B) all-cause death; (C) cardiovascular death; (D) LVEF.